These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 15867159)
21. Lithium, a potential protective drug in Alzheimer's disease. Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403 [TBL] [Abstract][Full Text] [Related]
22. Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. Wang HH; Li HL; Liu R; Zhang Y; Liao K; Wang Q; Wang JZ; Liu SJ J Alzheimers Dis; 2010; 21(1):167-79. PubMed ID: 20413892 [TBL] [Abstract][Full Text] [Related]
24. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992 [TBL] [Abstract][Full Text] [Related]
25. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486 [TBL] [Abstract][Full Text] [Related]
26. Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. Engel T; Goñi-Oliver P; Gomez-Ramos P; Morán MA; Lucas JJ; Avila J; Hernández F Neuroscience; 2008 Dec; 157(4):772-80. PubMed ID: 18951953 [TBL] [Abstract][Full Text] [Related]
27. IFN-γ promotes τ phosphorylation without affecting mature tangles. Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074 [TBL] [Abstract][Full Text] [Related]
28. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146 [TBL] [Abstract][Full Text] [Related]
29. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Caccamo A; Oddo S; Tran LX; LaFerla FM Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772 [TBL] [Abstract][Full Text] [Related]
30. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. Planel E; Bretteville A; Liu L; Virag L; Du AL; Yu WH; Dickson DW; Whittington RA; Duff KE FASEB J; 2009 Aug; 23(8):2595-604. PubMed ID: 19279139 [TBL] [Abstract][Full Text] [Related]
31. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. Forlenza OV; Spink JM; Dayanandan R; Anderton BH; Olesen OF; Lovestone S J Neural Transm (Vienna); 2000; 107(10):1201-12. PubMed ID: 11129110 [TBL] [Abstract][Full Text] [Related]
32. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370 [TBL] [Abstract][Full Text] [Related]
33. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. Lovell MA; Xiong S; Xie C; Davies P; Markesbery WR J Alzheimers Dis; 2004 Dec; 6(6):659-71; discussion 673-81. PubMed ID: 15665406 [TBL] [Abstract][Full Text] [Related]
34. Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3beta and PKA kinase activities. Delobel P; Flament S; Hamdane M; Delacourte A; Vilain JP; Buée L FEBS Lett; 2002 Apr; 516(1-3):151-5. PubMed ID: 11959122 [TBL] [Abstract][Full Text] [Related]
35. [The role of lithium in neurodegenerative diseases: new registries for old actors]. Pérez-Martínez DA Neurologia; 2009 Apr; 24(3):143-6. PubMed ID: 19418288 [TBL] [Abstract][Full Text] [Related]
36. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Hall GF; Lee VM; Lee G; Yao J Am J Pathol; 2001 Jan; 158(1):235-46. PubMed ID: 11141497 [TBL] [Abstract][Full Text] [Related]
37. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. Hong M; Chen DC; Klein PS; Lee VM J Biol Chem; 1997 Oct; 272(40):25326-32. PubMed ID: 9312151 [TBL] [Abstract][Full Text] [Related]
38. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295 [TBL] [Abstract][Full Text] [Related]
39. Tauopathies and tau oligomers. Takashima A J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895 [TBL] [Abstract][Full Text] [Related]